Stock CBMG CELLULAR BIOMEDICINE GROUP, INC.
Add to a list
To use this feature you must be a member
Log inSign up
Inactive Instrument

Press Releases Cellular Biomedicine Group, Inc.

Equities

CBMG

US15117P1021

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
CELLULAR BIOMEDICINE GROUP, INC. : Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Changes in Control or Registrant, Change in Directors or Principal Officers, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Other Events, Financial Statements and Exhibits (form 8-K)
AQ
Cellular Biomedicine Group :, Inc. Announces Completion of Merger
PR
CELLULAR BIOMEDICINE GROUP, INC. : Submission of Matters to a Vote of Security Holders, Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)
AQ
Cellular Biomedicine : CBMG Stockholders Approve Merger
PU
Cellular Biomedicine Group :, Inc. Stockholders Approve Merger
PR
CELLULAR BIOMEDICINE GROUP, INC. : Other Events (form 8-K)
AQ
Cellular Biomedicine : Leading Proxy Advisory Firms Glass Lewis and ISS Recommend CBMG Stockholders Vote FOR Proposed Merger
PU
CELLULAR BIOMEDICINE GROUP, INC. : Other Events (form 8-K)
AQ
Cellular Biomedicine : Leading Proxy Advisory Firms Glass Lewis and ISS Recommend Cellular Biomedicine Group Stockholders Vote FOR Proposed Merger
PR
Cellular Biomedicine : An Anti-BCMA CAR T-Cell Therapy (C-CAR088) Shows Promising Safety and Efficacy Profile in Relapsed or Refractory Multiple Myeloma
PU
Cellular Biomedicine : CBMG Announces Data to be Presented at 2020 ASH Annual Meeting
PU
CELLULAR BIOMEDICINE GROUP, INC. : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)
AQ
Cellular Biomedicine: 3Q Earnings Snapshot
AQ
Cellular Biomedicine : CBMG Reports Q3 2020 Financial Results and Business Highlights
PU
CELLULAR BIOMEDICINE : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-Q)
AQ
CELLULAR BIOMEDICINE GROUP, INC. : Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Unregistered Sale of Equity Securities, Financial Statements and Exhibits (form 8-K)
AQ
WeissLaw LLP : Reminds CBMG and MR Shareholders About Its Ongoing Investigations
PR
CELLULAR BIOMEDICINE GROUP, INC. : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)
AQ
Cellular Biomedicine Group : to Present at Chinese Biopharmaceutical Association-USA Annual Conference
PR
CELLULAR BIOMEDICINE INVESTOR ALERT By the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Cellular Biomedicine Group, Inc. - CBMG
BU
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. CBMG Stock
  4. News Cellular Biomedicine Group, Inc.
  5. Press Releases